Provided by Tiger Trade Technology Pte. Ltd.

NovoCure

15.63
-1.2200-7.24%
Pre-market: 15.59-0.0365-0.23%08:30 EDT
Volume:996.52K
Turnover:16.03M
Market Cap:1.82B
PE:-11.95
High:16.65
Open:16.56
Low:15.60
Close:16.85
52wk High:21.45
52wk Low:9.82
Shares:116.45M
Float Shares:96.42M
Volume Ratio:1.01
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3082
EPS(LYR):-1.2221
ROE:-43.22%
ROA:-9.26%
PB:5.38
PE(LYR):-12.79

Loading ...

Novocure Ltd : JP Morgan Resumes Coverage with Neutral Rating; Target Price $17

THOMSON REUTERS
·
Jul 13

Novocure to Report Q2 Results, Host Conference Call and Webcast

Reuters
·
Jul 01

Novocure to Report Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Jul 01

Novocure Wins CE Mark for Optune Pax in Locally Advanced Pancreatic Cancer Treatment

Reuters
·
Jun 30

Novocure’s Optune Pax® Receives Ce Mark for the Treatment of Locally Advanced Pancreatic Cancer

THOMSON REUTERS
·
Jun 30

Novocure - to Launch Optune Pax in Germany in Coming Weeks

THOMSON REUTERS
·
Jun 30

Wedbush Initiates a Hold Rating on NovoCure (NVCR)

TIPRANKS
·
Jun 23

Analysts Are Bullish on These Healthcare Stocks: NovoCure (NVCR), Ocular Therapeutix (OCUL)

TIPRANKS
·
Jun 22

Top Midday Decliners

MT Newswires Live
·
Jun 19

Sector Update: Healthcare Stocks Decline Thursday Afternoon

MT Newswires Live
·
Jun 19

NovoCure Down Nearly 18%, On Track for Largest Percent Decrease Since July 2025 -- Data Talk

Dow Jones
·
Jun 19

Novocure Price Target Cut to $46.00/Share From $48.00 by HC Wainwright & Co.

Dow Jones
·
Jun 19

BUZZ-U.S. STOCKS ON THE MOVE-Kardigan, Energy companies

Reuters
·
Jun 18

Analyst Maintains Buy on NovoCure, Trims Price Target to $46 Amid Shift to New Indications and Stable GBM Franchise

TIPRANKS
·
Jun 18

Novocure price target lowered to $46 from $48 at H.C. Wainwright

TIPRANKS
·
Jun 18

Novocure Limited : H.c. Wainwright Cuts Target Price to $46 From $48

THOMSON REUTERS
·
Jun 18

Novocure falls -18.2%

TIPRANKS
·
Jun 18

BUZZ-U.S. STOCKS ON THE MOVE-Pfizer, Accenture, Kroger

Reuters
·
Jun 18

Novocure's Late-Stage Trial For Tumor Treatment Misses Primary Endpoint

Dow Jones
·
Jun 18

Top Premarket Decliners

MT Newswires Live
·
Jun 18